The association between hormone therapy (estrogen, with or without progesterone) and colorectal cancer (CRC) has received considerable scientific interest but previous research has generated inconsistent results. We aimed to examine whether postdiagnostic use of hormone therapy might protect against CRC mortality and all-cause mortality. Women diagnosed with CRC between January 2007 and December 2012 were identified from the Swedish Cancer Registry and linked to the Swedish Prescribed Drug Register to retrieve hormone therapy users after CRC diagnosis. A total of 1,109 patients were diagnosed with CRC and used hormone therapy post-CRC diagnosis. Time-dependent Cox regression with 1-year lag was used to calculate the hazard ratio (HR) of CRC mortality and all-cause mortality associated with post-diagnostic use of hormone therapy. Use of hormone therapy after CRC diagnosis was associated with a 26% risk reduction in CRC mortality (HR 5 0.67, 95%CI 0.56-0.79) and a 30% risk reduction in all-cause mortality (HR 5 0.68, 95%CI 0.59-0.77). The risk reduction was even stronger if women also used hormone therapy before the diagnosis of CRC and for women with higher cumulative doses of hormone therapy. The risk reduction was largely consistent irrespective of CRC severity. Our data suggests that use of hormone therapy after CRC diagnosis is associated with a decreased risk of cancer-related mortality and all-cause mortality.
Introduction
The lower incidence of colorectal cancer (CRC) in women as compared to men suggests a possible protective effect of female hormones. 1 Since the 1980 sec, studies examining the associations between reproductive factors and use of exogenous sex hormones and CRC have received great interest. Some observational studies have found a decreased risk of CRC in women, who had been a previous or current user of menopausal hormones, compared to women who had never used menopausal hormones. [2] [3] [4] [5] [6] Other studies have shown inconsistent data with no association or a non-significant increased risk. 7, 8 A recent meta-analyses found consistent evidence supporting the association between estrogen-progesterone therapy (EPT) and CRC risk reduction. 9 The Women's Health Initiative (WHI) hormone therapy trials found a decreased risk of CRC among estrogen plus progestin users during the intervention phase but CRCs were diagnosed at an advanced stage. 10 For women solely using estrogen, no difference was noted as compared to the control group. 10 Further analyses after the intervention showed that the cumulative incidence of CRC in the study group was similar as compared to the control group. 11 The findings obtained from observational studies and clinical trials cannot be compared directly. The results from a randomized trial, such as WHI hormone therapy trials, are generally considered to be the gold standard. However, it is worth noting that the WHI was designed as a prevention study that mainly involved elderly women; around two-thirds of the women in the trials were 60 years of age or older before randomization. Although many studies have explored the association between hormone therapy and incidence of CRC, [2] [3] [4] [5] [6] only a few studies have explored whether hormone therapy can improve the survival of patients with CRC. [12] [13] [14] A study, which used the Nurses' Health Study cohorts, found that current postmenopausal estrogen use after diagnosis of colorectal cancer was associated with decreased mortality. 12 Using women without post-diagnostic use of hormone therapy as a reference, the primary aim of this population-based study, which was conducted in Sweden, was to explore whether the use of hormone therapy after CRC diagnosis is associated with a decreased risk of CRC mortality and all-cause mortality. In addition, we examined whether usage of hormone therapy before CRC diagnosis could modify the observed association. It is known that the usage of hormone therapy has decreased significantly since the publication of the WHI hormone therapy trials in 2002, 15, 16 which showed an increased risk of breast cancer and cardiovascular diseases among women receiving hormone therapy. In Sweden, use of hormone replacement therapy (HRT) has decreased from a peak of 36% in 1,999% to 27% in 2002 and further to 9% in 2007 among women aged between 50 and 59 years old. 15 We utilized this "natural experiment" 17 to examine whether the risk of death among women diagnosed with CRC in 2001 was different as compared to women diagnosed in 2003.
Methods

Study population
This retrospective cohort study was approved by the Ethics Committee at Lund University, Sweden. All women diagnosed with CRC between January 2007 and December 2012 were identified from the Swedish Cancer Registry. The Swedish Cancer Registry, which was founded in 1958 and is maintained by the National Board of Health and Welfare, has an estimated >90% completeness of nationwide coverage. 18 In Sweden, it is compulsory for clinicians and pathologists/cytologists to report all newly diagnosed cancers to the Cancer Registry. Since 2002, this registry has included primary tumor sites (coded using the International Classification of Diseases, 10th revision), and tumor characteristics according to the TNM system, including the size of tumor, nodal status and presence of metastatic disease. 19 The T, N and M categories were used to determine and create stage at diagnosis of CRC, [20] [21] [22] which ranged from stage I (the least advanced) to stage IV (the most advanced) as described previously. 21 Women who developed CRC between the age of 45 and 69 and had a clinical diagnosis of CRC were identified from the Swedish Cancer Register by using ICD codes C18, C19 and C20. Women in this age bracket were more likely to use hormone therapy. 23 Women with CRC were further linked to the Swedish Prescribed Drug Register to retrieve information about the use of hormone therapy (Figure 1 ). The Swedish Prescribed Drug Register (PDR) was established in July 2005 by the National Board of Health and Welfare. The PDR contains information about age and sex as well as information regarding drug utilization and expenditures for all prescribed drugs in the entire Swedish population. All drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification system. Drugs used for systemic hormone therapy were defined as oral and transdermal products within the following ATC-groups, 23 G03CA03 estradiol, G03CA57-conjugated estrogens, G03CX01 tibolone, G03FA01 norethisterone and estrogen, G03FA12 medroxyprogesterone and estrogen, G03FA15 dienogest and estrogen, G03FA17 drospirenone and estrogen, G03FB05 norethisterone and estrogen, G03FB06 medroxyprogesterone and estrogen, and G03FB09 levonorgestrel and estrogen. In Sweden, injectable preparations are not used. Furthermore, hormone therapy can only be dispensed for 3 months at a time in Sweden, thus women who were diagnosed with CRC after 2007 but without prescription of hormones between July 2005 and December 2006 can be treated as incident users of hormone therapy. All women who had been prescribed with oral and transdermal hormones were identified by using the ATC codes listed above. Up to five CRC patients, who had never been prescribed hormone therapy, were matched to women who used What's new? The lower incidence of colorectal cancer (CRC) in women as compared to men suggests a possible protective effect of female hormones. Although many studies have explored the association between hormone therapy and CRC incidence, only a few examined whether hormone therapy can improve the survival of patients. Using the Swedish Nationwide Cancer Register and Prescribed Drug Register, here the authors found that use of hormone therapy after CRC diagnosis was associated with a decreased risk of cancer-related mortality and all-cause mortality. The risk reduction of mortality was even stronger if women also used hormone therapy before the diagnosis of CRC. Cancer Epidemiology hormone therapy according to age at diagnosis and the clinical stage of CRC. Post-diagnostic use of hormone therapy was treated as a time-dependent variable in the regression model and lagged by 1 year, which meant that patients moved from a follow-up period of non-exposure (from diagnosis of CRC to 1 year after the prescription of hormone therapy) to a period of exposure (1 year after women being given the first prescription), then considered as exposed thereafter for the remainder of follow-up. All patients who died within 1 year after diagnosis were excluded in the study. CRC patients who died within 1 year after diagnosis were diagnosed at an advance stage (79% at stages 3 and 4) as compared to the general CRC patients (48% at stages of 3 and 4). In addition, we estimated the intensity of post-diagnostic use of hormone therapy by estimating the accumulated dose between the first and latest hormone prescription during the follow-up.
In Sweden, a dramatic decline has been observed in the use of hormone therapy following the 2002 release of the report from the WHI hormone trial. 11, 12 We utilized this "natural experiment" and identified women who were diagnosed with CRC in 2001 and 2003 using the same definitions described above. We aimed to examine whether the risk of death among women diagnosed with CRC in 2001 was lower as compared to those diagnosed in 2003 because the observed difference in this "natural experiment" was contributed mainly by hormone therapy use as CRC treatments were relatively consistent during the study periods. 24 We further linked the study cohort to Statistics Sweden's Total Population Register and to the Population Housing Census to obtain information on individual-level characteristics such as birth year, years of education; to the Cause of Death Register to identify date of death as well as the cause of death and to the Emigration Registry to identify date of emigration. All linkages were performed using individual national identification numbers, which were replaced with serial numbers to preserve anonymity.
Study outcome
From the Cause of Death Register, we identified all women who had died between January 2006 and December 2015. The primary outcome was death due to CRC (ICD codes: C18, C19 and C20) and the secondary outcome was death due to all the causes (ICD codes: A00-Z99).
Statistical analysis
Time-dependent Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for CRC mortality and all-cause mortality associated with postdiagnostic use of hormone therapy. Potential confounding was controlled by the selected clinical and demographic characteristics. The following characteristics were included in the model: age at diagnosis of CRC (modeled as a continuous variable); year at diagnosis of CRC (modeled as a continuous variable to account for follow-up time); stage of CRC (stage I to IV); country of birth (Sweden, European countries and others); highest educational level (<9, 9-11 or 12 years); family history of CRC (yes or no) and comorbidities with chronic ischemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease and hypertension (yes or no).
We calculated person-years at risk for our cohort from 1-year post-diagnosis of CRC to the earliest of death, emigration or the end of the study period (December 31, 2015). We censored individuals (i.e., treated them as no longer under observation or at risk of the study outcome) at the time of death from any cause, at the end of the follow-up period (December 31, 2013) or at the time of emigration, whichever came first. The proportional hazards assumption was tested using cumulative martingale residuals and the Kolmogorovbased supremum test. Data are accurate to two decimal places. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). After a mean of 5.4 years and accumulated 6,089 personyears of follow-up, 246 patients had died and 200 of them had died due to CRC ( Table 2 ). The corresponding incidence rate of all-cause mortality was 40.4 per 1,000 person-years for women with post-diagnostic use of hormone therapy, and 56.8 per 1,000 person-years for women without hormone therapy use. Use of hormone therapy after CRC diagnosis was associated with a 26% risk reduction in CRC mortality (HR 5 0.74, 95%CI 0.62-0.88) and a 30% risk reduction in all-cause mortality (HR 5 0.70, 95%CI 0.60-0.82) after adjusting all the confounding factors listed in Table 1 . For incidence users of hormone therapy after CRC diagnosis, the HR for CRC mortality was 0.79 (95%CI 0.58-1.07) and 0.80 (95%CI 0.60-1.05) for all-cause mortality. For women who had previously used hormone therapy before CRC diagnosis, the HR was 0.71 (95%CI 0.58-0.88) for CRC mortality and 0.66 (95%CI 0.55-0.80) for all-cause mortality. In Table 3 , we stratified the main analyses by hormone therapy subtype (estrogen or estrogen and progesterone), and average doses (lowest, middle-low, middle-high and highest). Women who used hormone therapy to a higher dose were associated with a greater risk reduction of both CRC mortality and all-cause mortality. However, only 126 women had used estrogen and progesterone therapy and the HR was not significant because of the wider confidence intervals.
Results
The analyses were further stratified by age at diagnosis of CRC and the clinical stage ( Table 4 ). The observed risk reduction of mortality was largely consistent irrespective of the clinical stage of CRC. However, the HR was not significant for women who were diagnosed with CRC between the ages of 50 and 59.
In Table 5 
Discussion
In this retrospective cohort study, we identified a total of 1,109 women who were diagnosed with CRC during 2007-2012 that had used hormone therapy after their diagnosis. Our main finding in our study is that the women who used hormone therapy after their CRC diagnosis had a 24% decrease in CRC mortality, and a 30% decrease in all-cause mortality, as compared to CRC patients that did not use hormone therapy. In addition, we found that women who had used hormone therapy before the diagnosis of CRC had an even more decreased risk of both CRC mortality and allcause mortality. Utilizing the "natural experiment" study design, we found that women who had been diagnosed with CRC in 2001 had a non-significant decreased risk of death as compared to women diagnosed in 2003. This finding strongly supports our observations and suggests that hormone therapy use might be associated with a risk reduction of mortality. To our knowledge, this is the first population-based study to explore whether using hormone therapy after CRC diagnosis might protect against CRC mortality and all-cause mortality. Numerous previous studies have examined the association between hormone therapy use and incident CRC but have yielded inconsistent results 2-8 possibly due to incomplete control of confounding factors and differences in patient populations. WHI randomized trials have Abbreviation: HR, hazard ratio. It was adjusted by age at diagnosis, year of diagnosis, birth country, education level, stage at diagnosis, family history and comorbidities.
reported a decreased incidence of CRC during the intervention phase stage, 10 however, further analyses after intervention did not find an association among them. 11 The data from WHI trials together with the discrepancy data from observational studies suggest that antitumor effects of hormone therapy on CRC might be modified by many other factors, such as the interval between menopause and hormone therapy use. Some previous studies have examined the association between hormone therapy and mortality in patients with CRC. [12] [13] [14] The study using the Nurses' Health Study cohorts found that current postmenopausal estrogen use before diagnosis of colorectal cancer was associated with decreased mortality. 12 Our data were consistent with the previous report and clearly showed that post diagnostic use of hormone therapy was associated with a decreased risk in CRC and all-cause mortalities. This observation was strongly supported by the "natural experiment" study design, which showed a non-significant decreased risk of death among women diagnosed with CRC in 2001 as compared to those diagnosed in 2003. The rate of hormone therapy in women had dropped greatly since the 2002 WHI publication. A "natural experiment" study design could account for many other confounding factors that were not included in the primary analyses. However, other factors, such as changes of CRC treatment, might contribute partly to the observed association.
Another finding is that women who used hormone therapy both before and after diagnosis of CRC were associated with a stronger risk reduction than women who started to use hormones after CRC diagnosis. Effect modification by pre-diagnostic use of HRT might be explained by a number of potential mechanisms. One potential mechanism could be that women who had used hormone therapy before CRC diagnosis might be associated with a longer duration and a high cumulative dose than those women that initiated hormone therapy after diagnosis. The second mechanism could be that pre-diagnostic use of hormone therapy might be associated with favorable CRC characteristics and result in improved CRC prognosis. However, our data had adjusted for stage at diagnosis of CRC, which suggests that its effect could be minimal. Third, health user bias, especially for those women with pre-diagnostic use of hormone therapy, might contribute somewhat to the observed effect modification. Use of hormone therapy has been reported to be associated with many favorable lifestyles and healthy behaviors such as having a cancer screening, which might lead to favorable tumor characteristics. 25, 26 In addition, these patients who continue to use hormone therapy after cancer diagnosis are most likely "healthier" patients who have a better prognosis. One way to deal with health user bias is to explore the association using incidence cases. We did find that an incident user showed an improved prognosis, but the HRs were not statistically significant because of small number of cases (Table 2 ). In addition, we adjusted for educational status, which means that we partly remedied this problem.
The underlying mechanism of the antitumor effect of postmenopausal exogenous hormone therapy on CRC remains unknown. Some data showed that estrogen exposure may protect against microsatellite instability (MSI), 27 and women who were taking estrogen plus progestin had a 40% reduction in CRC risk, especially for MSI-low or MSI-stable tumors. 28 A recent prospective study found that endogenous estrogen levels were negatively associated with colorectal cancer risk, suggesting that endogenous estrogens may protect against colorectal tumorigenesis. 29 In addition, postmenopausal hormone therapy might affect the metabolism of bile acid, 30, 31 and interfere with the function of insulin and insulin-like growth factor, 1,32-34 which might affect the subsequent development of CRC. 35, 36 This population-based study has a number of strengths and some limitations. An important strength is that it is a nationwide study and the number of patients included is large enough to guarantee reliable risk estimates. In addition, all the data were retrieved from Swedish registers that are of high quality and have national coverage. The prospective study design and the completeness of the follow-up of patients are other major advantages of our study. By linking several national registers in Sweden, we could identify some potential confounding factors, such as years of education, and countries of birth, which have been shown to be associated with CRC outcomes. 37, 38 In addition, we could adjust for tumor stage, which is the most significant factor that affects CRC outcome. One limitation of our study is the lack of information on some individual-level risk factors, such as medical treatments, smoking, screening and other dietary factors, which may have partly confounded our conclusion. However, we have adjusted for education level in our model, which may partly minimize the confounding effect of smoking and dietary factors. 39, 40 In addition, Sweden is a country with widespread availability of healthcare for all citizens at a minimal cost, thus discrepancy in medical treatment of CRC in Sweden is relatively uncommon. Another limitation is the possible exposure misclassifications because of the lack of certainty of medical adherence. In addition, stage of diagnosis was not controlled for the analyses in Table 4 as the data were not available. In summary, this population-based study indicates that the use of hormone therapy after CRC diagnosis is associated with a decreased risk of cancer-related mortality and allcause mortality. Risk reduction was even more pronounced in women who also used hormone therapy before the diagnosis of CRC. The findings from our study need to be confirmed by other observational studies. The underlying mechanisms need to be explored in further studies.
